ArticlePLoS neglected tropical diseases2026
Novel inhibitors against Cryptosporidium parvum through blocking its energy metabolism.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Through systematic structural optimization and modification of anti-Cryptosporidium parvum compound NSC158011 (N-1-naphthalenyl-2-(phenylthiol) ethane thioamide), we constructed a virtual compound library comprising 1,440 derivatives, and 29 derivatives were selected via molecular docking for chemical synthesis. Among them, eight derivatives exhibited significant inhibitory effects on LDH compared with NSC158011. In vitro examination found that two derivatives could markedly reduce the number of C. parvum in cells while exhibiting reduced toxicity. In vivo studies in model animals (IFN-γ knockout mouse) and native animals (calves) further validated the derivatives' potent anti-parasitic effects and their ability to alleviate intestinal villus atrophy caused by parasitic infections. Further investigations revealed that compound treatment was associated with upregulated expression of intestinal tight junction proteins (ZO-1, Occludin, Claudin-1) and downregulated the expression level of inflammatory protein Caspase-1. Analysis of the gut microbiota and metabolomics in calves indicated that treatment significantly restored the abundance of beneficial flora and regulated key metabolites, including isocitric acid and ornithine. The two derivatives identified in this study represent promising lead compounds for further development as anti-cryptosporidiosis agents, with potential relevance to livestock production and public health.
Indexed as
Identifiers
42832573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.